Business Wire

BEARINGPOINT

4.11.2020 07:32:10 CET | Business Wire | Press release

Share
BearingPoint Announces the Sale of Its Regulatory Technology Unit to Nordic Capital – RegTech Unit to Operate Independently in the Market

Management and technology consultancy BearingPoint will sell its independent Regulatory Technology (RegTech) business unit, a leading provider of software solutions for regulatory reporting to Nordic Capital, a leading private equity investor with a long history of developing technology companies and enabling and driving global growth. The transaction is a result of a strategic process to enable accelerated growth for the unit as a software company with specialized professional and managed services along the regulatory value chain.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201103005589/en/

With Nordic Capital as the new owner, the RegTech business will boost its leading market position and push ahead with its international expansion against the backdrop of regulatory harmonization. BearingPoint will continue to serve as a strategic consulting partner and will retain a minority stake in RegTech.

The current RegTech management team will remain and will work in close partnership with Nordic Capital. RegTech’s customers will not be impacted by the transaction. The closing of the transaction with Nordic Capital is subject to customary regulatory approvals. The financial terms of the transaction were not disclosed. The entire transaction has been managed by the M&A practice in BearingPoint’s Capital unit.

Kiumars Hamidian, Managing Partner with BearingPoint, said: "With the sale of our RegTech unit we accomplish the establishment of RegTech as a fully independent firm – a strategic initiative we had started two years ago. I said that 2020 is all about the execution of our Strategy 2025, and despite difficult market conditions because of Corona we stick to our long-term plans. Our current business performance is the best proof point that our strategy is paying off. With the transaction we are delivering on the ambitions lined out in our strategy: we intensify the focus on our market-leading consulting portfolio.

“The RegTech business unit will benefit from the increasing regulatory requirements around the world. As an independent firm, supported by a strong owner as Nordic Capital, it will have the necessary agility and flexibility to make the best possible use of these opportunities”, says Patrick Palmgren, Global Head of the BearingPoint Capital unit under which RegTech was managed so far. “I am personally looking forward to going on that journey together with Nordic Capital and RegTech”, Patrick Palmgren concludes.

Jürgen Lux, the CEO of RegTech, said: "We're delighted to welcome Nordic Capital to RegTech. The new ownership will support our further development and will also benefit our customers. With Nordic Capital we have a strong new partner at our side with extensive experience in developing and growing leading businesses in the software industry. We have used the past two years to enhance the autonomy of the RegTech business within the BearingPoint Group. Together with Nordic Capital, we have formed an ambitious growth agenda and will continue to invest in our proven, reliable and forward-looking software solution suite.”

Fredrik Näslund, Partner and Head of Technology & Payments, Nordic Capital Advisors added: “RegTech's unique portfolio of software and solutions is highly acclaimed in the industry and has already earned the trust of more than 6,000 reporting firms including banks, insurance companies, supervisory authorities and financial services providers. We are very impressed by the Company’s market position, its platform and its potential for further expansion. Our broad experience supporting the growth and development of software and technology companies makes Nordic Capital an ideal partner to play a formative role in the next phase for RegTech together with the Company’s management team.”

RegTech is a leading international provider of innovative solutions in regulatory and risk technology, tax technology and services for regulatory reporting along the regulatory value chain. Through close contact with supervisory authorities and as a member of key standardization committees, RegTech is actively involved in preparing and developing regulatory standards. With more than 25 years’ experience in the business, RegTech is firmly established as a market leader in Europe.

About BearingPoint

BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business critical services to its clients supporting their business success. The third unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.

BearingPoint's clients include many of the world's leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.

For more information, please visit:

Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye